Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
becatecarin
- Development stage
- Discontinued
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Becatecarin is a synthetic diethylaminoethyl (DEAE) analogue of the indolocarbazole glycoside antineoplastic antibiotic rebeccamycin. It is a water-soluble small molecule developed as an anticancer agent, primarily for the treatment of hepatobiliary duct tumors and biliary cancer, which are rare and aggressive cancers with limited treatment options. Becatecarin acts by intercalating into DNA and stabilizing the DNA-topoisomerase I complex, thereby interfering with topoisomerase I-catalyzed DNA breakage-reunion reactions. This leads to DNA cleavage and apoptosis in cancer cells. Becatecarin also exhibits activity as a weak substrate for the ABCG2 transporter, which may contribute to drug resistance in some tumor types[1][2][3][4][5].
- Other names
- 6-(2-(diethylamino)ethyl)-rebeccamycinDEAE-rebeccamycin analogueRebeccamycin analogue
02
Targets
TOP2A (DNA topoisomerase II)ABCG2 (Breast cancer resistance protein)TOP1 (DNA Topoisomerase I)TOP2B (DNA topoisomerase II beta)
Beyond the preview
Go deeper on becatecarin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on becatecarin.